In this model, simvastatin, used as either preventive or rescue therapy, has shown to decrease RhoA/ROCK signaling in hypoxia-induced PPHN, decreasing PVR, RV hypertrophy, and pulmonary arterial remodeling (59). Here, RHOA is linked to persistent fetal circulation syndrome.